论文部分内容阅读
目的:探讨对妊娠期内肝胆汁淤积症患者实施治疗时联合应用熊去氧胆酸、腺苷蛋氨酸的临床有效性。方法:将2016年1月至2016年12月70例在惠州市第六人民医院接受治疗的妊娠期内肝胆汁淤积症患者随机分成两个组,接受熊去氧胆酸、腺苷蛋氨酸治疗的37例为联合组,单独接受熊去氧胆酸治疗的33例为单药组,观察比对两组临床有效性。结果:治疗后,联合组谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBIL)、总胆汁酸(TBA)明显较单药组低,且联合组治疗总有效率是97.3%,相较于单药组的78.8%明显较高,联合组不良妊娠结局发生率则明显较单药组低,差异具有统计学意义(P<0.05)。结论:对妊娠期内肝胆汁淤积症患者实施治疗时,联合应用熊去氧胆酸与腺苷蛋氨酸可提高治疗效果,进而有效改善妊娠结局。
Objective: To investigate the clinical efficacy of ursodeoxycholic acid and adenosylmethionine in the treatment of patients with hepatobiliary cholestasis during pregnancy. Methods: From January 2016 to December 2016, 70 patients with hepatic cholestasis who were treated in the Sixth People’s Hospital of Huizhou City during pregnancy were randomly divided into two groups, treated with ursodeoxycholic acid and adenosylmethionine Thirty-seven patients in the combined group received treatment with ursodeoxycholic acid alone for the single drug group. The clinical efficacy of the two groups was observed and compared. Results: After treatment, ALT, TBIL and TBA in the combination group were significantly lower than those in the single drug group, and the total effective rate in the combination group was 97.3 %, Which was significantly higher than that of the single drug group (78.8%). The incidence of adverse pregnancy outcomes in the combination group was significantly lower than that in the single drug group (P <0.05). CONCLUSIONS: Ursodeoxycholic acid and adenosylmethionine can improve the therapeutic effect in the treatment of patients with hepatobiliary cholestasis during pregnancy, and then effectively improve the pregnancy outcome.